The FY25 Defense Appropriations Act is anticipated to provide funding for the Ovarian Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members and all women impacted by this disease. The Congressionally Directed Medical Research Programs, or CDMRP, at the U.S. Army Medical Research and Development Command is the program office managing these anticipated FY25 funding opportunities.
The Full-Year Continuing Appropriations and Extensions Act of 2025 provides $650M in funding for the CDMRP. Congress provided further guidance for CDMRP program-level funding, including funding for the Prostate Cancer Research Program. The FY25 PCRP intends to support innovative, high-impact prostate cancer research.
